1
|
Matorras R, Chaudhari VS, Roeder C, Schwarze JE, Bühler K, Hwang K, Chang-Woo C, Iniesta S, D'Hooghe T, Mathur R. Evaluation of costs associated with fertility treatment leading to a live birth after one fresh transfer: A global perspective. Best Pract Res Clin Obstet Gynaecol 2023; 89:102349. [PMID: 37327667 DOI: 10.1016/j.bpobgyn.2023.102349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 04/27/2023] [Accepted: 05/07/2023] [Indexed: 06/18/2023]
Abstract
Considerable costs are associated with infertility treatment, but little evidence is available on the main drivers of treatment costs. This cost analysis investigated key costs for treatment with assisted reproductive technology (ART) and the proportion of costs attributed to the acquisition of recombinant human follicle-stimulating hormone (r-hFSH) alfa originator for one fresh embryo transfer (ET) leading to a live birth in Spain, Norway, the UK, Germany, Denmark, South Korea, Australia, and New Zealand. The total costs for one ART cycle with a fresh ET leading to a live birth varied between countries (€4108-€12,314). Costs for pregnancy and live birth were the major contributors in European countries, and the costs of oocyte retrieval, monitoring during ovarian stimulation, pregnancy, and live birth were the top contributors in the Asia-Pacific countries, included in this analysis. Acquisition costs for r-hFSH alfa originator contributed to only 5%-17% of the total costs of one ART cycle with one fresh ET leading to a live birth.
Collapse
Affiliation(s)
- R Matorras
- Department of Obstetrics and Gynecology, Human Reproduction Unit, Cruces University Hospital, Basque Country University, Bizkaia, Bilbao, Spain; BioCruces Health Research Institute, Spain; Instituto Valenciano de Infertilidad, IVI Bilbao, IVIRMA, Bilbao, Spain
| | - V S Chaudhari
- EMD Serono Research & Development Institute, Inc., Billerica, USA.
| | - C Roeder
- Pharma Value Consulting, Switzerland
| | - J E Schwarze
- Merck Healthcare, Merck KGaA, Darmstadt, Germany
| | - K Bühler
- Scientific Centre for Endometriosis, University Hospitals of Saarland, Saarbrücken, Germany; Department of Gynecology, Jena-University Hospital-Friedrich Schiller University, Jena, Germany
| | - K Hwang
- Cha University, Fertility Centre, Bundang Medical Centre, Seongnam, Gyeonggi-do, South Korea
| | - C Chang-Woo
- Seoul Maria Fertility Hospital, Seoul, South Korea
| | - S Iniesta
- Department of Obstetrics, Gynecology and Reproductive Medicine, La Paz University Hospital, Madrid, Spain; Department of Reproductive Medicine, Ruber Internacional Hospital, Madrid, Spain
| | - T D'Hooghe
- Merck Healthcare, Merck KGaA, Darmstadt, Germany; Department of Development and Regeneration, Laboratory of Endometrium, Endometriosis & Reproductive Medicine, KU Leuven, Leuven, Belgium; Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University Medical School, New Haven, USA
| | - R Mathur
- Department of Reproductive Medicine and Surgery, Manchester Academic Health Sciences Centre, Manchester, UK
| |
Collapse
|
2
|
Domar A, Vassena R, Dixon M, Costa M, Vegni E, Collura B, Markert M, Samuelsen C, Guiglotto J, Roitmann E, Boivin J. Barriers and factors associated with significant delays to initial consultation and treatment for infertile patients and partners of infertile patients. Reprod Biomed Online 2021; 43:1126-1136. [PMID: 34756644 DOI: 10.1016/j.rbmo.2021.09.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Revised: 08/09/2021] [Accepted: 09/02/2021] [Indexed: 11/28/2022]
Abstract
RESEARCH QUESTION What are the key drivers and barriers for infertile patients and their partners to see an infertility specialist and initiate treatment? DESIGN An online, international, 30-minute quantitative survey collected data from 1944 respondents from nine countries. Respondents were infertile patients (n = 1037) or partners of infertile patients (n = 907; but not necessarily partners of the patient sample), at different stages of the treatment journey. RESULTS The overall average times were 3.2 years to receiving a medical infertility diagnosis, 2.0 years attempting to achieve pregnancy without assistance before treatment, and 1.6 years of treatment before successful respondents achieved pregnancy. The most common driver for considering treatment after a consultation (n = 1025) was an equal desire within the couple to have a child (40.8%). Of the partners (n = 356), 29.8% reported that transparency of information from healthcare professionals about treatment expectations was important. A significantly higher proportion of respondents seeking treatment reported that healthcare professionals offered supportive services (61.2%) and mental health services (62.0%), than of the 207 respondents who did not seek treatment (32.4% and 36.7%, respectively; P < 0.001). Perceived cost was the most commonly reported barrier for respondents not seeking a consultation (37.5% of n = 352) or treatment (42.0% of n = 207). Of the 95 respondents who discontinued treatment, 34.7% discontinued due to the financial impact. CONCLUSIONS Respondents reported significant delays to seeking treatment, probably negatively impacting the chances of achieving pregnancy. Motivational coherence within couples was a key driver and cost of treatment was the main barrier. Reported supportive service offerings by healthcare professionals were significantly associated with continuation of the treatment journey.
Collapse
Affiliation(s)
- Alice Domar
- Boston IVF, Domar Center for Mind/Body Health, Waltham, MA and Harvard Medical School, Boston MA, USA.
| | | | - Marjorie Dixon
- ANOVA Fertility and Reproductive Health, University of Toronto, Toronto ON, Canada
| | - Mauro Costa
- Reproductive Medicine, International Evangelical Hospital, Genova, Italy
| | - Elena Vegni
- Department of Health Sciences, Università Statale di Milano, Milan, Italy
| | - Barbara Collura
- RESOLVE: The National Infertility Association, McClean, Virginia, USA
| | - Marie Markert
- Ferring Pharmaceuticals, Health Economics & Outcomes Research, Copenhagen, Denmark
| | - Carl Samuelsen
- Ferring Pharmaceuticals, Health Economics & Outcomes Research, Copenhagen, Denmark
| | | | | | - Jacky Boivin
- School of Psychology, Cardiff University, Cardiff, UK
| |
Collapse
|
3
|
Barrenetxea G, García-Velasco JA, Aragón B, Osset J, Brosa M, López-Martínez N, Coroleu B. Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: Cost-minimization analysis based on the PURSUE study. REPRODUCTIVE BIOMEDICINE & SOCIETY ONLINE 2018; 5:46-59. [PMID: 29774275 PMCID: PMC5952674 DOI: 10.1016/j.rbms.2018.01.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 11/24/2017] [Accepted: 01/25/2018] [Indexed: 05/31/2023]
Abstract
This study presents an economic assessment of controlled ovarian stimulation in assisted reproductive technology procedures in Spain, comparing the use of corifollitropin alfa and various forms of recombinant follicle-stimulating hormone (rFSH) in women of advanced maternal age. A cost-minimization analysis (CMA) was performed to assess the cost per cycle of controlled controlled ovarian stimulation, including only direct costs associated with the stimulation phase. The CMA was based on the population characteristics, the protocol, and the results obtained from the PURSUE study, taking into account 9 days of controlled controlled ovarian stimulation and 300 IU rFSH/day. The primary analysis included pharmacological costs alone. Different scenarios were evaluated including various doses and possible additional days (0-5) for rFSH. For the alternative analyses, the total costs (direct pharmacological costs, costs of visits and follow-up tests, and any additional pharmacological costs) were considered in both the private and public sectors. Treatment with corifollitropin alfa resulted in a lower pharmacological cost compared with rFSH (€757.25 and €950.30, respectively), creating a saving of approximately -20%. The results of the scenario analyses showed that corifollitropin alfa reduced the pharmacological cost of controlled ovarian stimulation in comparison with daily administration of doses ≥ 250 IU rFSH (considering same daily dose for all days), regardless of the additional days required (7-12 days) (average -€223; range -€488 to -€44). In conclusion, in addition to the efficacy shown in the PURSUE study, the use of corifollitropin alfa results in a decrease in the direct costs associated with controlled ovarian stimulation in older women in Spain.
Collapse
Affiliation(s)
- Gorka Barrenetxea
- Universidad del País Vasco/Euskal Herriko Unibertsitatea, Reproducción Bilbao, Bilbao, Spain
| | | | - Belén Aragón
- Merck Sharp & Dohme de España S.A., Madrid, Spain
| | - Jordi Osset
- Merck Sharp & Dohme de España S.A., Madrid, Spain
| | - Max Brosa
- Oblikue Consulting S.L., Barcelona, Spain
| | | | - Buenaventura Coroleu
- Service of Reproductive Medicine, Department of Obstetrics, Gynaecology and Reproduction, Hospital Universitario Dexeus, Barcelona, Spain
| |
Collapse
|